Emboss Medical Completes Asset Acquisition of Novadien Healthcare
September 24, 2020
News highlights:
Emboss Medical acquires assets of Novadien Healthcare, including Circumplast®, that is clinically proven to be the most innovative, elegant and efficient male child circumcision device available.
Emboss Medical continues to invest in and expand sales globally of Circumplast® to individual doctors, small practices, clinics, hospitals and blue chip organisations.
Cambridge, UK – September 24, 2020 – Emboss Medical Limited signs asset purchase and confirmatory IP assignment agreements with Novadien Healthcare Pty. Ltd, assigning and transferring right, title and IP to Emboss Medical Limited. Resulting from the asset acquisition, Emboss Medical Limited has now the right and title to Circumplast®.
Circumplast®, clinically proven to be the most innovative, elegant and efficient male child circumcision device available, is in high demand by successful organisations, practices, clinics and hospitals around the world. The Circumplast® device is FDA registered and ISO and CE cleared, and has been awarded an Innovative Technology designation seal by Vizient. The Vizient award recognises Circumplast® as a breakthrough value-based solution, that raises the standard of patient care and safety, whilst simultaneously reducing the risk of harm to patients.
By acquiring Circumplast®, Emboss Medical Limited is well positioned to uniquely and successfully address requirements for male child circumcision, raising much needed standards of patient care and safety, whilst reducing risks. Emboss Medical Limited is pleased to be in a position to lead in the growing market of male child circumcision, and one that addresses public health concerns. Emboss Medical Limited is further investing in and expanding sales globally of Circumplast®.
